# Galera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/galera-therapeutics

- Industry: Biotechnology
- Headquarters: Malvern, US
- Website: www.galeratx.com/
- Total disclosed funding: $147M
- Latest round: Series C (Aug 30, 2018)
- Investors on record: 16

## About

Galera Therapeutics, Inc., based in the US, focuses on developing innovative therapies aimed at improving treatment outcomes for breast cancer patients through proprietary technologies that enhance the efficacy of existing therapies.Galera Therapeutics, Inc. specializes in developing therapies for breast cancer treatment. Founded in Malvern, US, the company has engaged in 10 deals, with its most recent funding occurring on February 15, 2023. The latest round was a Private Placement/Follow On, raising USD 30.00 mn. The firm’s founder, Robert Beardsley, has a history in the biotechnology sector, and the current CEO is Sorensen Mel.Galera Therapeutics, Inc. specializes in developing innovative therapies specifically targeting breast cancer treatment. The company's core product offerings revolve around proprietary technologies designed to enhance the anti-cancer efficacy of existing therapies, ultimately aiming to provide improved treatment outcomes for patients. These novel therapies focus on addressing significant unmet medical needs in the breast cancer patient population and enhancing the quality of life. Galera Therapeutics primarily serves healthcare providers, oncologists, and patients in the United States and select international markets, committed to advancing research within the oncology landscape.Galera Therapeutics generates revenue through partnerships and collaborations within the healthcare sector, primarily focusing on pharmaceutical companies and clinical research organizations. The firm’s revenue model capitalizes on the successful development and commercialization of its flagship therapeutics, which are positioned to impact breast cancer treatment paradigms. Specific pricing plans for individual therapies align with industry standards and are typically negotiated within the framework of collaborative agreements or direct sales to healthcare providers and institutions.In February 2023, Galera Therapeutics raised USD 30.00 mn in a private placement to support the completion of its Phase 3 clinical trial. The company aims to launch new therapies designed to further enhance treatment options for breast cancer patients. Additionally, Galera is looking to expand its market presence into select international regions, with specific strategies being developed for these efforts. The recent funding will primarily be utilized to advance their clinical trials and support their growth in new geographic markets.

## Funding rounds

- Series C, Aug 30, 2018, $70M — New Enterprise Associates, Sofinnova Investments, HBM Partners, Novartis Venture Fund, Novo Holdings, Clarus Ventures, Tekla Capital Management, Adage Capital Management, Correlation Ventures, BioGenerator, RA Capital Management, Rock Springs Capital, Nan Fung Life Sciences, Galera Angels
- Series B, Nov 28, 2016, $15M — Sofinnova Investments
- Series B, Feb 3, 2016, $5M — Enso Ventures
- Series B, Oct 14, 2015, $37M — New Enterprise Associates, Novartis Venture Fund, Novo Holdings, Correlation Ventures
- Series A, Mar 19, 2015, $4.7M — New Enterprise Associates, Novartis Venture Fund, Correlation Ventures
- Series A, Aug 6, 2014, $4.7M — New Enterprise Associates, Novartis Venture Fund
- Series A, Dec 10, 2012, $11M — New Enterprise Associates, Novartis Venture Fund, Correlation Ventures
- Seed, Jun 15, 2010 — ABC Laboratories, Inc., BioGenerator

## Investors

- ABC Laboratories, Inc. — Seed
- BioGenerator (https://capitalatlas.ai/funds/biogenerator) — Seed, Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B, Series C
- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Series A, Series B, Series C
- Novo Holdings — Series B, Series C
- Enso Ventures (https://capitalatlas.ai/funds/enso-ventures) — Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B, Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C
- Adage Capital Management — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Rock Springs Capital — Series C
- Nan Fung Life Sciences — Series C
- Galera Angels — Series C